Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activity

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 8, 2007, Pages 2365-2371

  Judd, Andrew S ^a   Souers, Andrew J ^a   Wodka, Dariusz ^a   Zhao, Gang ^a   Mulhern, Mathew M ^a   Iyengar, Rajesh R ^a   Gao, Ju ^a   Lynch, John K ^a   Freeman, Jennifer C ^a   Falls, H Douglas ^a   Brodjian, Sevan ^a   Dayton, Brian D ^a   Reilly, Regina M ^a   Gintant, Gary ^a   Limberis, James T ^a   Mikhail, Ann ^a   Leitza, Sandra T ^a   Houseman, Kathryn A ^a   Diaz, Gilbert ^a   Bush, Eugene N ^a   Shapiro, Robin ^a   Knourek Segel, Victoria ^a   Hernandez, Lisa E ^a   Marsh, Kennan C ^a   Sham, Hing L ^a   Collins, Christine A ^a   Kym, Philip R ^a   more..

^a ABBOTT LABORATORIES   (United States)

Author keywords

hERG; MCHr1; Obesity; Patch clamp

Indexed keywords

CHROMONE DERIVATIVE; MELANIN CONCENTRATING HORMONE; POTASSIUM CHANNEL HERG;

ARTICLE; BINDING AFFINITY; DRUG SYNTHESIS; EVALUATION; PATCH CLAMP; PROTON NUCLEAR MAGNETIC RESONANCE;

AMIDES; ANIMALS; CHROMONES; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; OBESITY; PATCH-CLAMP TECHNIQUES; PHARMACOKINETICS; RECEPTORS, PITUITARY HORMONE;

EID: 33947583439     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.11.068     Document Type: Article

References (29)

1. Saito Y., Nothacker H.-P., and Civelli O. Trends Endocrinol. Metab. 11 (2000) 299
2. Schwartz M.W., Woods S.C., Porte Jr. D., Selley R.J., and Baskin D.G. Nature 404 (2000) 661
3. Ludwig D.S., Tritos N.A., Mastaitis J.W., Kulkarni R., Kokkotou E., Elmquist J., Lowell B., Flier J.S., and Maratos-Flier E. J. Clin. Invest. 107 (2001) 379
4. Shimada M., Tritos N.A., Lowell B.B., Flier J.S., and Maratos-Flier E. Nature 396 (1998) 670
5. Chen Y., Hu C., Hsu C.-K., Zhang Q., Bi C., Asnicar M., Hsiung H.M., Fox N., Slieker L.J., Yang D.D., Heiman M.L., and Shi Y. Endocrinology 143 (2002) 2469
6. Marsh D.J., Weingarth D.T., Novi D.E., Chen H.Y., Trumbauer M.E., Chen A.S., Guan X.-M., Jiang M.M., Feng Y., Camacho R.E., Shen Z., Frazier E.G., Yu H., Metzger J.M., Kuca S.J., Shearman L.P., Gopal-Truter S., MacNeil D.J., Strack A.M., MacIntyre D.E., Van der Ploeg L.H.T., and Qian S. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 3240
7. Multiple patents describing small molecule MCHr1 antagonists have published recently. For excellent reviews on the subject, see the following: (a). Kowalski T.J., and McBriar M.D. Expert Opin. Invest. Drugs 13 (2004) 1113
8. Browning A. Expert Opin. Ther. Pat 14 (2004) 313
9. Collins C.A., and Kym P.R. Curr. Opin. Invest. Drugs 4 (2003) 386
10. For example, see: (a). Borowsky B., Durkin M.M., Ogozalek K., Marzabadi M.R., DeLeon J., Lagu B., Heurich R., Lichtblau H., Shaposhnik Z., Daniewska I., Blackburn T.P., Branchek T.A., Gerald C., Vaysse P.J., and Forray C. Nat. Med. 8 (2002) 779
11. Takekawa S., Asami A., Ishihara Y., Terauchi J., Kato K., Shimomura Y., Mori M., Murakoshi H., Kato K., Suzuki N., Nishimura O., and Fujino M. Eur. J. Pharmacol. 438 (2002) 129
12. Souers A.J., Gao J., Brune M., Bush E., Wodka D., Vasudevan A., Judd A.S., Mulhern M.M., Brodjian S., Dayton B., Shapiro R., Hernandez L.E., Marsh K.C., Sham H.L., Collins C.A., and Kym P.R. J. Med. Chem. 48 (2005) 1318
13. Kym P.R., Iyengar R.R., Souers A.J., Lynch J.K., Judd A.S., Gao J., Freeman J.C., Mulhern M.M., Zhao G., Vasudevan A., Wodka D., Blackburn C., Brown J., Che J.L., Cullis C., Lai S.J., LaMarche M., Marsilje T., Roses J., Sells T., Geddes B., Govek E., Patane M., Fry D., Dayton B.D., Brodjian S., Falls H.D., Brune M., Bush E., Shapiro R., Knourek-Segel V., Fey T., McDowell C., Reinhart G.A., Preusser L.C., Marsh K., Hernandez L., Sham H.L., and Collins C.A. J. Med. Chem. 48 (2005) 5888
14. Kym P.R., Souers A.J., Campbell T.J., Lynch J.K., Judd A.S., Iyengar R., Vasudevan A., Gao J., Freeman J.C., Wodka D., Mulhern M., Zhao G., Wagaw S., Napier J.J., Brodjian S., Dayton B.D., Reilly R.M., Segreti J., Fryer R.M., Preusser L.C., Reinhart G.A., Hernandez L., Marsh K.C., Sham H.L., Collins C.A., and Polakowski J.S. J. Med. Chem. 49 (2006) 2339
15. McBriar M.D., Guzik H., Shapiro S., Paruchova J., Xu R., Palani A., Clader J.W., Cox K., Greenlee W.J., Hawes B.E., Kowalski T.J., O'Neill K., Spar B.D., Weig B., Weston D.J., Farley C., and Cook J.J. J. Med. Chem. 49 (2006) 2294
16. For reviews of the hERG channel and QT interval prolongation, see: (a). Finalyson K., Witchel H.J., McCulloch J., and Sharkey J. Eur. J. Pharmacol. 500 (2004) 129
17. Fermini B., and Fossa A.A. Nat. Rev. Drug Discov. 2 (2003) 439
18. Lynch, J. K.; Freeman, J. C.; Judd, A. S.; Iyengar, R.; Mulhern, M.; Zhao, G.; Napier, J. J.; Wodka, D.; Brodjian, S.; Dayton, B. D.; Falls, D.; Ogiela, C.; Reilly, R. M.; Campbell, T. J.; Polakowski, J. S.; Hernandez, L.; Marsh, K. C.; Shapiro, R.; Knourek-Segel, V.; Droz, B.; Bush, E.; Brune, M.; Preusser, L. C.; Fryer, R. M.; Reinhart, G. A.; Houseman, K.; Diaz, G.; Mikhail, A.; Limberis, J. T.; Sham, H. L.; Collins, A. A.; Kym, P. R. J. Med. Chem. 2006, ASAP, doi:10.1021/jm060683e.
19. Fry D., Dayton B.D., Brodjian S., Ogiela C., Sidorowicz H., Frost L.J., McNally T., Reilly R.M., and Collins C.A. Int. J. Biochem. Cell Biol. 38 (2006) 1290
20. Souers, A. J.; Iyengar, R.; Judd, A. S.; Beno, D. W. A.; Gao, J.; Zhao, G.; Brune, M. E.; Napier, J. J.; Mulhern, M. M.; Lynch, J. K.; Freeman, J. C.; Wodka, D.; Chen, C. J.; Falls, H. D.; Brodjian, S.; Dayton, B. D.; Diaz, G.; Bush, E.; Shapiro, R.; Droz, B.; Knourek-Segel, V.; Hernandez, L. E.; Marsh, K. C.; Sham, H. L.; Collins, C. A.; Kym, P. R. Bioorg. Med. Chem. Lett. 2006, doi:10.1016/j.bmcl.2006.11.061.
21. For related papers, see: (a). McBriar M.D., Guzik H., Shapiro S., Xu R., Paruchova J., Clader J.W., O'Neill K., Hawes B., Sorota S., Margulis M., Tucker K., Weston D.J., and Cox K. Bioorg. Med. Chem. Lett. 16 (2006) 4262
22. Meyers, K. M.; Kim, N.; Méndez-Andino, J. L.; Hu, X. E.; Mumin, R. N.; Klopfenstein, S. R.; Wos, J. A.; Mitchell, M. C.; Paris, J. L.; Ackley, D. C.; Holbert, J. K.; Mittelstadt, S. W.; Reizes, O. Bioorg. Med. Chem. Lett. 2006, doi:10.1016/j.bmcl.2006.10.053.
23. Iyengar, R. R.; Lynch, J. K.; Mulhern, M. M.; Judd, A. S.; Freeman, J. C.; Gao, J.; Souers, A. J.; Zhao, G.; Falls, H. D.; Brodjian, S.; Dayton, B. D.; Reilly, R. M.; Swanson, S.; Su, Z.; Martin, R. L.; Leitza, S. T.; Housman, K. A.; Diaz, G.; Collins, C. A.; Sham, H. L.; Kym, P. R. Bioorg. Med. Chem. Lett. 2006, doi:10.1016/j.bmcl.2006.11.065.
24. a of the alkyl dicyclopropylamine's conjugate acid within 4g to be ∼5.5-6.5. For the synthesis and properties of alkyl dicyclopropylamines, see:. Gillaspy M.L., Lefker B.A., Hada W.A., and Hoover D.J. Tetrahedron Lett. 36 (1995) 7399
25. For a review of tactics used to ameliorate hERG cross-reactivity of small molecules, see:. Jamieson C., Moir E.M., Rankovic Z., and Wishart G. J. Med. Chem. 49 (2006) 1
26. As added perspective, consider that analog 1 also caused 90% inhibition of the hERG tail current at 7 μM drug concentration.
27. At the end of study, mice treated with 16a were found to have statistically significant weight loss, having a 5% difference in this parameter with respect to non-treated control animals. Cumulative food and caloric intake were significantly decreased in the drug-treated group without any overt behavioral abnormalities noted in Irwin or Edge tests.
28. End of study trough levels in the heart and thigh were 76.8 and 3.20 μg/g, respectively.
29. For a recent review of cationic amphiphilic drugs, see:. Reasor M.J., and Kacew S. Exp. Biol. Med. 226 (2001) 825